With $825M SPAC merger, ProKidney sets stage for phase 3 trial of kidney disease cell therapy

Chamath Palihapitiya’s special purpose acquisition company is throwing its weight behind ProKidney. The merger will give ProKidney $825 million to fund phase 3 development of a cell therapy designed to slow, stabilize and reverse decline in kidney function.